B.Riley reiterates Buy on Aspen Aerogels stock, $9 target

B. Riley reiterated its Buy rating and $9.00 price target on Aspen Aerogels, whose shares were quoted at $5.87 and were up 107% year to date; InvestingPro analysis described them as overvalued relative to its Fair Value estimates. Management expects to return to positive adjusted EBITDA in Q3 2026 and maintain or grow its approximately $63 million year-end net cash position, citing subsea and LNG backlogs with visibility into 2027 and beyond and potential battery-storage revenue of tens of millions annually without meaningful capex. Separately, Q2 2026 adjusted loss of $0.28 per share missed the $0.2275 loss estimate, while revenue of $49.85 million exceeded the $41.61 million forecast.

Analysis

ASPN’s near-term setup is a credibility test, not simply an EV-demand call. If OEM production catches up with retail sales, the key transmission is higher utilization of already-won programs; GM’s reported sales are not a direct measure of ASPN-sourced units, so verify customer-specific shipments before extrapolating. European BEV penetration and OEM awards are leading indicators, not proof of awarded content converting into production revenue. A stronger counterweight to EV volatility is the industrial backlog: subsea/LNG visibility could support revenue diversification, but backlog conversion, margins, and working-capital needs matter more than duration claims alone.

The BESS opportunity is potentially valuable because management describes it as low-capex, but it remains an option until customer wins, shipment timing, and contribution economics are disclosed. Likewise, adjusted EBITDA breakeven would not by itself establish durable free-cash-flow generation. The prior revenue beat alongside a larger-than-expected adjusted loss makes margin conversion and cash use the critical checks.

Near term, the 107% YTD rise and bullish broker reiteration leave limited room for execution slippage; do not treat the broker’s target as independent validation. Over 1–3 months, monitor production-linked EV shipments, adjusted EBITDA, and net cash. Over 6–18 months, success depends on EV program ramp and industrial/BESS diversification. Thesis weakens if sourced volumes fail to track production, EBITDA remains negative beyond guidance, or net cash erodes materially. GM and Honda sales data alone do not establish a material earnings read-through for either automaker.

Key Decisions for Investors

• ASPN: avoid chasing the rally; wait for the next reporting update to confirm customer-specific shipment growth, adjusted EBITDA progress, and cash preservation. Reassess a long only if those metrics improve together, rather than on EV penetration or awards alone.
• For investors seeking a defined-risk bearish expression, consider a small ASPN put spread after a failed operating update, with strikes and expiry set only after checking option liquidity and implied volatility. The thesis is execution slippage against elevated expectations; cap risk at the debit and invalidate it if shipments and cash conversion confirm guidance.
• Track BESS separately as an upside catalyst: require named customer/qualification evidence, timing, and economics before capitalizing management’s revenue potential. Backlog visibility without conversion or cash-flow evidence is not sufficient to underwrite the bull case.